Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00532935 | MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066) | PHASE3 | COMPLETED | 517 | — | — | Jan 26, 2008 | Oct 23, 2009 | Jun 9, 2017 | - | — |
| NCT00482729 | MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED) | PHASE3 | COMPLETED | 1,246 | — | — | Jun 19, 2007 | Apr 27, 2009 | Jun 9, 2017 | - | — |
A1C is measured as a percent. Thus this change from baseline reflects the Week 32 A1C percent minus the baseline A1C percent
A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Sitagliptin phosphate (+) metformin hydrochloride |
| 2 | ACTIVE_COMPARATOR | pioglitazone |
| Name | Type | Description |
|---|---|---|
| sitagliptin phosphate (+) metformin hydrochloride | DRUG | sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an \~32 wk treatment period |
| Comparator: pioglitazone | DRUG | pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an \~32-wk treatment period. |
| metformin | DRUG | metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period |
General Inclusion Criteria: * Patient has type 2 diabetes mellitus * Patient is inadequately controlled and not on treatment with insulin or oral antihyperglycemic therapy General Exclusion Criteria: * Patient has a history of type 1 diabetes mellitus or history of ketoacidosis * Patient was on a...